Patrick P. Starlinger, M.D., Ph.D.

The purpose of this study is to assess the safety and tolerability of orally administered HRX215 in patients who underwent minor (pilot phase) or major (main study phase) liver resection due to metastases of a colon carcinoma.

The purpose of this study is to evaluate the impact of tranexamic acid (TXA) on perioperative blood transfusion in patients undergoing liver resection. The rationale for this study includes: (1) experimental evidence supporting the use of TXA in other surgical populations; (2) lack of evidence in patients undergoing liver resection; (3) clinical uncertainty and extensive support amongst hepatobiliary surgeons, anaesthesiologists, and hematologists for this proposed trial; (4) a feasible and efficient study design; and (5) the importance of the question: incidence of blood transfusion in patients undergoing liver resection is high, and the consequences serious. Participants enrolled in the prior Vanguard study will proceed directly into the RCT.